^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) + camizestrant (AZD9833) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SERENA-1: Results from a Phase 1 study (Parts I/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer
Published date:
12/02/2023
Excerpt:
Camizestrant 75 mg QD in combination with capivasertib 400 mg BID was well tolerated and associated with encouraging clinical and pharmacodynamic activity. These data support further evaluation of this combination in women with ER+/HER2− advanced breast cancer.
